Trump Announces Drug Price Deals With Nine More Pharma Companies

President Donald Trump announced on Monday that his administration has reached deals with nine more pharmaceutical companies to reduce drug prices for American patients, a move he hailed as a major expansion of his signature affordability initiative.

Speaking in the Oval Office flanked by pharmaceutical executives, Trump said the agreements represent a significant step forward in his “most favored nation” (MFN) drug pricing program, which he said has been sought for years.

“I’m thrilled to announce a major expansion of one of our signature affordability initiatives, something that people have been trying to get for years, for decades, and I’m not even sure that other presidents tried,” Trump said.

The nine companies—Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB—have committed to providing their lowest drug prices for American patients under the MFN framework, according to the White House.

The deals guarantee that every state Medicaid program will have access to MFN prices for all products from these companies. The White House projects the agreements will save Americans billions of dollars nationwide.

According to the administration, the lowered costs will apply to drugs treating a range of conditions, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer. The deals also ensure that any new innovative medicines these companies launch will automatically carry MFN pricing.

Beyond pricing, the companies have pledged a collective $19.6 billion investment in U.S. manufacturing. Additionally, some firms are donating substantial quantities of ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), a federal stockpile designed to shore up the domestic drug supply chain.

These nine agreements bring the total number of MFN deals secured by the Trump administration to 26 since last fall, according to the White House. With these additions, nearly 90 percent of the branded drug market is now covered by the initiative.

Earlier participants in the MFN program include AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Regeneron, Sanofi, Johnson & Johnson, and AbbVie.

The announcement underscores the administration’s continued focus on drug pricing as a key policy objective, with Trump framing the MFN initiative as a long-sought victory for American patients and taxpayers.

Critics have previously raised concerns about the feasibility and potential side effects of the MFN approach, but the White House touted Monday’s announcement as evidence that the program is gaining momentum and delivering tangible savings.

The deals come as part of a broader effort by the administration to address healthcare costs, a recurring theme in Trump’s political messaging. Monday’s event served as a visual demonstration of that priority, with executives from the newly signed companies standing alongside the president.

Observers note that the inclusion of such a wide array of pharmaceutical companies—from global giants to specialty drugmakers—signals broad industry engagement with the MFN framework, despite initial resistance from some sectors of the pharmaceutical industry.

The financial commitments to U.S. manufacturing are also seen as a strategic move to bolster domestic production capacity, which became a focus during the COVID-19 pandemic when supply chain vulnerabilities were exposed.

While the White House projected billions in savings, the actual impact on patient out-of-pocket costs will depend on how the MFN prices are implemented across state Medicaid programs and whether commercial insurers adopt similar pricing structures.

With nearly 90 percent of the branded drug market now under MFN agreements, the administration argues that the program is on track to deliver on its promise of lower drug prices. The remaining 10 percent of the market includes companies that have not yet signed on, though the White House expressed optimism that additional deals would follow.

Monday’s announcement is likely to feature in Trump’s ongoing political narrative as he continues to emphasize his administration’s accomplishments on healthcare and affordability.

Source: www.breitbart.com — https://www.breitbart.com/politics/2026/08/31/trump-reaches-deals-with-nine-more-pharmaceutical-companies-to-slash-drug-prices/